Authors
Latest:
Forward Looking NMIBC Treatment Advancements and Needs in 2024In this final episode, panelists conclude with reflections on the significant progress made in treating NMIBC over the past decade, particularly in the last 5 years. Looking ahead to 2024, experts in urology express excitement about investigational treatments (ie, cretostimogene grenadenorepvec and UGN 102), the potential for personalized medicine, emphasizing the need to understand molecular characteristics of the disease for better treatment customization. The session also highlights the importance of balancing quality of life with effective treatment strategies, and the prospect of utilizing emerging therapies early in the disease process.
Latest:
Investigators identify new target for VTE prevention"This study identifies a new target for VTE prevention," writes Kate Gessner, MD, PhD, and Philip Abbosh, MD, PhD.
Latest:
Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate CancerExperts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.
Latest:
A physician’s advice for defusing patient angerRebekah Bernard, MD, provides tips for improving interactions with patients who are angry.
Latest:
Urology Practice advice: prioritize billing and coding oversightWhen a miscoded procedure is the result of substantial negligence or fraud, it can be detrimental to a medical practice or physician.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Urologic Consultants has joined Solaris HealthLeading West Michigan practice now affiliated with nation’s largest urological healthcare management company
Latest:
Radical nephrectomy before or after systemic therapy for mRCCRecent research has revived the controversy regarding the role of cytoreductive nephrectomy in this setting.
Latest:
How text messaging can be a valuable tool for your practiceHere are seven ways texting can improve healthcare revenue and decrease costs.
Latest:
Integrating video visits into urologic training"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.
Latest:
FDA fast tracks trastuzumab deruxtecan for HER2+ tumors, including bladder cancerThe application is based on findings from the phase 2 DESTINY-PanTumor02 trial.
Latest:
Online reviews are crucial to maintaining a thriving health care practiceIndependent health care practices rely on online ratings and reviews to attract new patients and establish themselves as leading, recognizable providers in their community.
Latest:
Managing your online reputation in health careWhile online reviews are critical in any industry, patient expectations are simply different when it comes to health care.
Latest:
Neoadjuvant chemoimmunotherapy combo shows promise in UTUCThe phase 2 study explored the combination of the PD-1 inhibitor toripalimab and chemotherapy as neoadjuvant treatment for patients with upper tract urothelial carcinoma.
Latest:
Register Today! UH Urology Institute’s Fall SymposiumsUniversity Hospitals Urology Institute is excited to announce that this coming fall, the department is hosting 2 educational courses in cutting-edge urologic specialties: female sexual health and gender care.
Latest:
Allina Health Cancer Institute 2022 Symposium reimagines cancer careThe symposium brings together clinicians devoted to solving the disease of cancer and the many challenges associated with it.
Latest:
Letter: Declassifying Gleason 6 as a cancer would do more harm than good"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.
Latest:
Abiraterone-based triplet boosts survival in de novo mCSPCFindings from the PEACE-1 trial published in the Lancet showed that adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved overall survival in patients with de novo metastatic castration-sensitive prostate cancer.
Latest:
Why favor high intensity focused ultrasound for treating localized prostate cancer?"HIFU allows us to treat where we want and not where we don’t," writes Jennifer Linehan, MD.
Latest:
Smaller medical practices increasingly targeted for cyber attacksPatient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.
Latest:
The aging surgeon: A geriatrician's perspective"We all need to revisit meaningful methods for ongoing assurance of competency specific to our fields of medicine and surgery across the physician career span," writes Hal H. Atkinson, MD, MS.
Latest:
Novel intravesical drug delivery systems explored in bladder cancer"TAR-200 is a sort of a pretzel device. It's a novel drug delivery mechanism that's placed inside the bladder for sustained release of gemcitabine," explains Siamak Daneshmand, MD.
Latest:
Expert advice on improving interactions with difficult patients“Patients will never change, and demanding family members will never change. The solution to the problem is to manage the way we think about them,” writes Joan Naidorf, DO.
Latest:
BCG-unresponsive NMIBC: Current evidence and optionsMultiple investigational agents have been developed and are being studied.
Latest:
Malpractice Consult: What to know about closing arguments"All the components of the trial are designed to try to ensure that when the jurors depart for the deliberation room, they are inclined to find for the attorney’s side in the case," writes Austin Richards, Esq.
Latest:
Future Directions for the Management of Advanced Prostate CancerBobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.
Latest:
Financial toxicity is a growing concern in urologic oncology"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.
Latest:
Management of BCG-unresponsive NMIBC"An alternative off-label option for patients with BCG-unresponsive NMIBC is sequential intravesical gemcitabine and docetaxel (Gem/Doce)," write Rachel Passarelli, MD, and Vignesh T. Packiam, MD.
